GEO Accession viewer

GSM5603884	Whole blood, healthy individual, no treatment 4
GSM5603885	Whole blood, healthy individual, no treatment 5
GSM5603886	Whole blood, healthy individual, no treatment 6
GSM5603887	Whole blood, healthy individual, no treatment 7
GSM5603888	Whole blood, healthy individual, no treatment 8
GSM5603889	Whole blood, healthy individual, no treatment 9
GSM5603890	Whole blood, healthy individual, no treatment 10
GSM5603891	Whole blood, SLE patient 53 Dose 4 on Week 12, placebo
GSM5603892	Whole blood, SLE Patient 145 Dose 4 on Week 12 ; IFN-K
GSM5603893	Whole blood, SLE Patient 143 Dose 4 on Week 12 ; IFN-K
GSM5603894	Whole blood, SLE patient 61 Dose 4 on Week 12, placebo
GSM5603895	Whole blood, SLE patient 54 Dose 4 on Week 12, placebo
GSM5603896	Whole blood, SLE patient 16 Dose 4 on Week 12, placebo
GSM5603897	Whole blood, SLE patient 57 Dose 4 on Week 12, placebo
GSM5603898	Whole blood, SLE Patient 138 Dose 4 on Week 12 ; IFN-K
GSM5603899	Whole blood, SLE Patient 156 Dose 4 on Week 12 ; IFN-K
GSM5603900	Whole blood, SLE patient 51 Dose 4 on Week 12, placebo
GSM5603901	Whole blood, SLE patient 18 Dose 4 on Week 12, placebo
GSM5603902	Whole blood, SLE Patient 102 Dose 5 on Week 24; IFN-K
GSM5603903	Whole blood, SLE Patient 152 Dose 4 on Week 12 ; IFN-K
GSM5603904	Whole blood, SLE patient 52 Dose 4 on Week 12, placebo
GSM5603905	Whole blood, SLE Patient 140 Dose 4 on Week 12 ; IFN-K
GSM5603906	Whole blood, SLE patient 56 Dose 4 on Week 12, placebo
GSM5603907	Whole blood, SLE Patient 99 Dose 4 on Week 12 ; IFN-K
GSM5603908	Whole blood, SLE Patient 102 Follow-up on Week 36 ; IFN-K
GSM5603909	Whole blood, SLE Patient 103 Dose 4 on Week 12 ; IFN-K
GSM5603910	Whole blood, SLE patient 51 Dose 5 on Week 24, placebo
GSM5603911	Whole blood, SLE patient 56 Follow-up on Week 36, placebo
GSM5603912	Whole blood, SLE Patient 138 Dose 5 on Week 24 ; IFN-K
GSM5603913	Whole blood, SLE Patient 139 Dose 5 on Week 24 ; IFN-K
GSM5603914	Whole blood, SLE Patient 156 Follow-up on Week 36 ; IFN-K
GSM5603915	Whole blood, SLE patient 51 Follow-up on Week 36, placebo
GSM5603916	Whole blood, SLE Patient 140 Follow-up on Week 36 ; IFN-K
GSM5603917	Whole blood, SLE Patient 152 Follow-up on Week 36 ; IFN-K
GSM5603918	Whole blood, SLE patient 54 Follow-up on Week 36, placebo
GSM5603919	Whole blood, SLE Patient 139 Follow-up on Week 36 ; IFN-K
GSM5603920	Whole blood, SLE Patient 146 Follow-up on Week 36 ; IFN-K
GSM5603921	Whole blood, SLE patient 52 Follow-up on Week 36, placebo
GSM5603922	Whole blood, SLE Patient 145 Dose 1 on Week 0; IFN-K
GSM5603923	Whole blood, SLE Patient 138 Dose 1 on Week 0; IFN-K
GSM5603924	Whole blood, SLE patient 53 Dose 1 on Week 0, placebo
GSM5603925	Whole blood, SLE patient 18 Dose 1 on Week 0, placebo
GSM5603926	Whole blood, SLE Patient 144 Dose 1 on Week 0; IFN-K
GSM5603927	Whole blood, SLE Patient 143 Dose 1 on Week 0; IFN-K
GSM5603928	Whole blood, SLE patient 57 Dose 1 on Week 0, placebo
GSM5603929	Whole blood, SLE patient 55 Dose 1 on Week 0, placebo
GSM5603930	Whole blood, SLE Patient 156 Dose 1 on Week 0; IFN-K
GSM5603931	Whole blood, SLE patient 16 Dose 1 on Week 0, placebo
GSM5603932	Whole blood, SLE Patient 102 Dose 1 on Week 0; IFN-K
GSM5603933	Whole blood, SLE Patient 103 Follow-up on Week 36 ; IFN-K
GSM5603934	Whole blood, SLE patient 53 Follow-up on Week 36, placebo
GSM5603935	Whole blood, SLE Patient 143 Follow-up on Week 36 ; IFN-K
GSM5603936	Whole blood, SLE Patient 146 Dose 5 on Week 24 ; IFN-K
GSM5603937	Whole blood, SLE Patient 99 Dose 5 on Week 24; IFN-K
GSM5603938	Whole blood, SLE patient 16 Follow-up on Week 36, placebo
GSM5603939	Whole blood, SLE patient 54 Dose 5 on Week 24, placebo
GSM5603940	Whole blood, SLE patient 52 Dose 5 on Week 24, placebo
GSM5603941	Whole blood, SLE Patient 147 Dose 5 on Week 24 ; IFN-K
GSM5603942	Whole blood, SLE Patient 140 Dose 5 on Week 24 ; IFN-K
GSM5603943	Whole blood, SLE Patient 156 Dose 5 on Week 24 ; IFN-K
GSM5603944	Whole blood, SLE patient 58 Dose 5 on Week 24, placebo
GSM5603945	Whole blood, SLE patient 56 Dose 5 on Week 24, placebo
GSM5603946	Whole blood, SLE patient 57 Dose 5 on Week 24, placebo
GSM5603947	Whole blood, SLE patient 18 Dose 5 on Week 24, placebo
GSM5603948	Whole blood, SLE Patient 152 Dose 5 on Week 24 ; IFN-K
GSM5603949	Whole blood, SLE patient 61 Dose 5 on Week 24, placebo
GSM5603950	Whole blood, SLE patient 16 Dose 5 on Week 24, placebo
GSM5603951	Whole blood, SLE Patient 145 Dose 5 on Week 24 ; IFN-K
GSM5603952	Whole blood, SLE Patient 144 Dose 5 on Week 24 ; IFN-K
GSM5603953	Whole blood, SLE Patient 143 Dose 5 on Week 24 ; IFN-K
GSM5603954	Whole blood, SLE Patient 146 Dose 4 on Week 12 ; IFN-K
GSM5603955	Whole blood, SLE Patient 147 Dose 4 on Week 12 ; IFN-K
GSM5603956	Whole blood, SLE patient 53 Dose 5 on Week 24, placebo
GSM5603957	Whole blood, SLE Patient 144 Dose 4 on Week 12; IFN-K
GSM5603958	Whole blood, SLE Patient 152 Dose 1 on Week 0; IFN-K
GSM5603959	Whole blood, SLE patient 58 Dose 1 on Week 0, placebo
GSM5603960	Whole blood, SLE Patient 99 Dose 1 on Week 0; IFN-K
GSM5603961	Whole blood, SLE patient 51 Dose 1 on Week 0, placebo
GSM5603962	Whole blood, SLE Patient 139 Dose 1 on Week 0; IFN-K
GSM5603963	Whole blood, SLE Patient 103 Dose 1 on Week 0; IFN-K
GSM5603964	Whole blood, SLE Patient 139 Dose 4 on Week 12 ; IFN-K
GSM5603965	Whole blood, SLE patient 61 Dose 1 on Week 0, placebo
GSM5603966	Whole blood, SLE Patient 102 Dose 4 on Week 12; IFN-K
GSM5603967	Whole blood, SLE patient 58 Dose 4 on Week 12, placebo
GSM5603968	Whole blood, SLE patient 55 Dose 4 on Week 12, placebo
GSM5603969	Whole blood, SLE Patient 140 Dose 1 on Week 0; IFN-K
GSM5603970	Whole blood, SLE Patient 147 Dose 1 on Week 0; IFN-K
GSM5603971	Whole blood, SLE patient 52 Dose 1 on Week 0, placebo
GSM5603972	Whole blood, SLE patient 54 Dose 1 on Week 0, placebo
GSM5603973	Whole blood, SLE patient 56 Dose 1 on Week 0, placebo
GSM5603974	Whole blood, SLE patient 55 Dose 5 on Week 24, placebo
GSM5603975	Whole blood, SLE Patient 99 Follow-up on Week 36 ; IFN-K
GSM5603976	Whole blood, SLE patient 55 Follow-up on Week 36, placebo
GSM5603977	Whole blood, SLE Patient 103 Dose 5 on Week 24 ; IFN-K
GSM5603978	Whole blood, SLE patient 18 Follow-up on Week 36, placebo
GSM5603979	Whole blood, SLE patient 61 Follow-up on Week 36, placebo
GSM5603980	Whole blood, SLE patient 58 Follow-up on Week 36, placebo
GSM5603981	Whole blood, SLE patient 57 Follow-up on Week 36, placebo
GSM5603982	Whole blood, SLE Patient 144 Follow-up on Week 36 ; IFN-K
GSM5603983	Whole blood, SLE Patient 145 Follow-up on Week 36 ; IFN-K
GSM5603984	Whole blood, SLE Patient 138 Follow-up on Week 36 ; IFN-K
GSM5603985	Whole blood, SLE Patient 147 Follow-up on Week 36 ; IFN-K
GSM5603986	Whole blood, SLE Patient 146 Dose 1 on Week 0; IFN-K
GSM5603987	Whole blood, SLE patient 45 Dose 1 on Week 0, placebo
GSM5603988	Whole blood, SLE Patient 110 Dose 4 on Week 12; IFN-K
GSM5603989	Whole blood, SLE Patient 111 Follow-up on Week 36; IFN-K
GSM5603990	Whole blood, SLE Patient 90 Follow-up on Week 36; IFN-K
GSM5603991	Whole blood, SLE Patient 92 Follow-up on Week 36; IFN-K
GSM5603992	Whole blood, SLE patient 30 Follow-up on Week 36, placebo
GSM5603993	Whole blood, SLE Patient 110 Follow-up on Week 36; IFN-K
GSM5603994	Whole blood, SLE patient 11 Follow-up on Week 36, placebo
GSM5603995	Whole blood, SLE Patient 93 Follow-up on Week 36 ; IFN-K
GSM5603996	Whole blood, SLE patient 6 Follow-up on Week 36, placebo
GSM5603997	Whole blood, SLE patient 6 Dose 1 on Week 0, placebo
GSM5603998	Whole blood, SLE Patient 110 Dose 1 on Week 0; IFN-K
GSM5603999	Whole blood, SLE patient 5 Dose 1 on Week 0, placebo
GSM5604000	Whole blood, SLE patient 30 Dose 1 on Week 0, placebo
GSM5604001	Whole blood, SLE Patient 90 Dose 1 on Week 0; IFN-K
GSM5604002	Whole blood, SLE Patient 92 Dose 1 on Week 0; IFN-K
GSM5604003	Whole blood, SLE patient 11 Dose 1 on Week 0, placebo
GSM5604004	Whole blood, SLE Patient 93 Dose 1 on Week 0; IFN-K
GSM5604005	Whole blood, SLE Patient 111 Dose 1 on Week 0; IFN-K
GSM5604006	Whole blood, SLE patient 5 Dose 4 on Week 12, placebo
GSM5604007	Whole blood, SLE patient 6 Dose 4 on Week 12, placebo
GSM5604008	Whole blood, SLE Patient 111 Dose 4 on Week 12; IFN-K
GSM5604009	Whole blood, SLE patient 11 Dose 4 on Week 12, placebo
GSM5604010	Whole blood, SLE Patient 92 Dose 4 on Week 12; IFN-K
GSM5604011	Whole blood, SLE patient 30 Dose 4 on Week 12, placebo
GSM5604012	Whole blood, SLE Patient 90 Dose 4 on Week 12; IFN-K
GSM5604013	Whole blood, SLE patient 5 Dose 5 on Week 24, placebo
GSM5604014	Whole blood, SLE Patient 93 Dose 4 on Week 12; IFN-K
GSM5604015	Whole blood, SLE Patient 90 Dose 5 on Week 24; IFN-K
GSM5604016	Whole blood, SLE patient 30 Dose 5 on Week 24, placebo
GSM5604017	Whole blood, SLE Patient 110 Dose 5 on Week 24; IFN-K
GSM5604018	Whole blood, SLE patient 6 Dose 5 on Week 24, placebo
GSM5604019	Whole blood, SLE Patient 92 Dose 5 on Week 24; IFN-K
GSM5604020	Whole blood, SLE Patient 111 Dose 5 on Week 24; IFN-K
GSM5604021	Whole blood, SLE patient 11 Dose 5 on Week 24, placebo
GSM5604022	Whole blood, SLE patient 5 Follow-up on Week 36, placebo
GSM5604023	Whole blood, SLE Patient 93 Dose 5 on Week 24; IFN-K
GSM5604024	Whole blood, SLE Patient 131 Dose 1 on Week 0; IFN-K
GSM5604025	Whole blood, SLE patient 42 Dose 1 on Week 0, placebo
GSM5604026	Whole blood, SLE patient 45 Dose 4 on Week 12, placebo
GSM5604027	Whole blood, SLE Patient 131 Dose 4 on Week 12; IFN-K
GSM5604028	Whole blood, SLE patient 47 Dose 1 on Week 0, placebo
GSM5604029	Whole blood, SLE patient 42 Dose 4 on Week 12, placebo
GSM5604030	Whole blood, SLE patient 47 Dose 4 on Week 12, placebo
GSM5604031	Whole blood, SLE patient 45 Dose 5 on Week 24, placebo
GSM5604032	Whole blood, SLE Patient 131 Dose 5 on Week 24; IFN-K
GSM5604033	Whole blood, SLE patient 42 Dose 5 on Week 24, placebo
GSM5604034	Whole blood, SLE patient 47 Dose 5 on Week 24, placebo
GSM5604035	Whole blood, SLE patient 45 Follow-up on Week 36, placebo
GSM5604036	Whole blood, SLE Patient 131 Follow-up on Week 36; IFN-K
GSM5604037	Whole blood, SLE patient 42 Follow-up on Week 36, placebo
GSM5604038	Whole blood, SLE patient 47 Follow-up on Week 36, placebo
GSM5604039	Whole blood, SLE patient 63 Follow-up on Week 36, placebo
GSM5604040	Whole blood, SLE Patient 148 Follow-up on Week 36 ; IFN-K
GSM5604041	Whole blood, SLE patient 20 Follow-up on Week 36, placebo
GSM5604042	Whole blood, SLE Patient 137 Follow-up on Week 36; IFN-K
GSM5604043	Whole blood, SLE Patient 151 Follow-up on Week 36 ; IFN-K
GSM5604044	Whole blood, SLE patient 17 Follow-up on Week 36, placebo
GSM5604045	Whole blood, SLE patient 62 Follow-up on Week 36, placebo
GSM5604046	Whole blood, SLE patient 17 Dose 1 on Week 0, placebo
GSM5604047	Whole blood, SLE Patient 137 Dose 4 on Week 12 ; IFN-K
GSM5604048	Whole blood, SLE patient 20 Dose 4 on Week 12, placebo
GSM5604049	Whole blood, SLE patient 15 Dose 4 on Week 12, placebo
GSM5604050	Whole blood, SLE Patient 150 Dose 5 on Week 24; IFN-K
GSM5604051	Whole blood, SLE patient 63 Dose 5 on Week 24, placebo
GSM5604052	Whole blood, SLE patient 62 Dose 4 on Week 12, placebo
GSM5604053	Whole blood, SLE Patient 148 Dose 4 on Week 12 ; IFN-K
GSM5604054	Whole blood, SLE patient 63 Dose 4 on Week 12, placebo
GSM5604055	Whole blood, SLE patient 15 Dose 1 on Week 0, placebo
GSM5604056	Whole blood, SLE patient 20 Dose 1 on Week 0, placebo
GSM5604057	Whole blood, SLE patient 17 Dose 4 on Week 12, placebo
GSM5604058	Whole blood, SLE Patient 151 Dose 4 on Week 12; IFN-K
GSM5604059	Whole blood, SLE Patient 153 Dose 5 on Week 24 ; IFN-K
GSM5604060	Whole blood, SLE patient 20 Dose 5 on Week 24, placebo
GSM5604061	Whole blood, SLE patient 15 Dose 5 on Week 24, placebo
GSM5604062	Whole blood, SLE Patient 153 Dose 1 on Week 0; IFN-K
GSM5604063	Whole blood, SLE Patient 137 Dose 1 on Week 0; IFN-K
GSM5604064	Whole blood, SLE Patient 153 Dose 4 on Week 12 ; IFN-K
GSM5604065	Whole blood, SLE Patient 141 Dose 1 on Week 0; IFN-K
GSM5604066	Whole blood, SLE Patient 141 Dose 5 on Week 24 ; IFN-K
GSM5604067	Whole blood, SLE Patient 141 Dose 4 on Week 12 ; IFN-K
GSM5604068	Whole blood, SLE patient 63 Dose 1 on Week 0, placebo
GSM5604069	Whole blood, SLE patient 17 Dose 5 on Week 24, placebo
GSM5604070	Whole blood, SLE Patient 148 Dose 1 on Week 0; IFN-K
GSM5604071	Whole blood, SLE Patient 141 Follow-up on Week 36 ; IFN-K
GSM5604072	Whole blood, SLE Patient 151 Dose 1 on Week 0; IFN-K
GSM5604073	Whole blood, SLE Patient 148 Dose 5 on Week 24 ; IFN-K
GSM5604074	Whole blood, SLE Patient 137 Dose 5 on Week 24 ; IFN-K
GSM5604075	Whole blood, SLE Patient 150 Dose 1 on Week 0; IFN-K
GSM5604076	Whole blood, SLE patient 62 Dose 1 on Week 0, placebo
GSM5604077	Whole blood, SLE Patient 150 Dose 4 on Week 12 ; IFN-K
GSM5604078	Whole blood, SLE patient 62 Dose 5 on Week 24, placebo
GSM5604079	Whole blood, SLE Patient 151 Dose 5 on Week 24 ; IFN-K
GSM5604080	Whole blood, SLE Patient 150 Follow-up on Week 36 ; IFN-K
GSM5604081	Whole blood, SLE Patient 153 Follow-up on Week 36 ; IFN-K
GSM5604082	Whole blood, SLE patient 15 Follow-up on Week 36, placebo
GSM5604083	Whole blood, SLE patient 31 Dose 5 on Week 24, placebo
GSM5604084	Whole blood, SLE patient 2 Dose 5 on Week 24, placebo
GSM5604085	Whole blood, SLE patient 35 Dose 5 on Week 24, placebo
GSM5604086	Whole blood, SLE Patient 125 Dose 5 on Week 24; IFN-K
GSM5604087	Whole blood, SLE patient 3 Dose 5 on Week 24, placebo
GSM5604088	Whole blood, SLE Patient 114 Dose 5 on Week 24; IFN-K
GSM5604089	Whole blood, SLE Patient 107 Dose 4 on Week 12; IFN-K
GSM5604090	Whole blood, SLE patient 29 Dose 5 on Week 24, placebo
GSM5604091	Whole blood, SLE patient 31 Dose 4 on Week 12, placebo
GSM5604092	Whole blood, SLE Patient 112 Dose 4 on Week 12; IFN-K
GSM5604093	Whole blood, SLE Patient 112 Dose 1 on Week 0; IFN-K
GSM5604094	Whole blood, SLE patient 37 Dose 4 on Week 12, placebo
GSM5604095	Whole blood, SLE Patient 117 Dose 4 on Week 12; IFN-K
GSM5604096	Whole blood, SLE patient 35 Dose 1 on Week 0, placebo
GSM5604097	Whole blood, SLE Patient 125 Dose 1 on Week 0; IFN-K
GSM5604098	Whole blood, SLE Patient 125 Dose 4 on Week 12; IFN-K
GSM5604099	Whole blood, SLE patient 29 Dose 4 on Week 12, placebo
GSM5604100	Whole blood, SLE patient 2 Dose 4 on Week 12, placebo
GSM5604101	Whole blood, SLE Patient 94 Dose 4 on Week 12; IFN-K
GSM5604102	Whole blood, SLE Patient 114 Dose 4 on Week 12; IFN-K
GSM5604103	Whole blood, SLE patient 3 Dose 4 on Week 12, placebo
GSM5604104	Whole blood, SLE Patient 117 Dose 1 on Week 0; IFN-K
GSM5604105	Whole blood, SLE patient 31 Dose 1 on Week 0, placebo
GSM5604106	Whole blood, SLE patient 35 Dose 4 on Week 12, placebo
GSM5604107	Whole blood, SLE Patient 107 Dose 1 on Week 0; IFN-K
GSM5604108	Whole blood, SLE patient 37 Dose 1 on Week 0, placebo
GSM5604109	Whole blood, SLE patient 29 Dose 1 on Week 0, placebo
GSM5604110	Whole blood, SLE patient 2 Dose 1 on Week 0, placebo
GSM5604111	Whole blood, SLE Patient 114 Dose 1 on Week 0; IFN-K
GSM5604112	Whole blood, SLE Patient 94 Dose 1 on Week 0; IFN-K
GSM5604113	Whole blood, SLE patient 3 Dose 1 on Week 0, placebo
GSM5604114	Whole blood, SLE patient 35 Follow-up on Week 36, placebo
GSM5604115	Whole blood, SLE patient 3 Follow-up on Week 36, placebo
GSM5604116	Whole blood, SLE Patient 114 Follow-up on Week 36; IFN-K
GSM5604117	Whole blood, SLE Patient 94 Dose 5 on Week 24; IFN-K
GSM5604118	Whole blood, SLE Patient 112 Dose 5 on Week 24; IFN-K
GSM5604119	Whole blood, SLE Patient 107 Follow-up on Week 36; IFN-K
GSM5604120	Whole blood, SLE Patient 117 Dose 5 on Week 24; IFN-K
GSM5604121	Whole blood, SLE Patient 94 Follow-up on Week 36; IFN-K
GSM5604122	Whole blood, SLE patient 37 Dose 5 on Week 24, placebo
GSM5604123	Whole blood, SLE patient 29 Follow-up on Week 36, placebo
GSM5604124	Whole blood, SLE patient 31 Follow-up on Week 36, placebo
GSM5604125	Whole blood, SLE Patient 117 Follow-up on Week 36 ; IFN-K
GSM5604126	Whole blood, SLE Patient 125 Follow-up on Week 36; IFN-K
GSM5604127	Whole blood, SLE patient 37 Follow-up on Week 36, placebo
GSM5604128	Whole blood, SLE patient 2 Follow-up on Week 36, placebo
GSM5604129	Whole blood, SLE Patient 107 Dose 5 on Week 24; IFN-K
GSM5604130	Whole blood, SLE Patient 112 Follow-up on Week 36; IFN-K
GSM5604131	Whole blood, SLE Patient 142 Dose 1 on Week 0; IFN-K
GSM5604132	Whole blood, SLE patient 59 Dose 4 on Week 12, placebo
GSM5604133	Whole blood, SLE patient 23 Dose 4 on Week 12, placebo
GSM5604134	Whole blood, SLE Patient 155 Dose 4 on Week 12 ; IFN-K
GSM5604135	Whole blood, SLE Patient 105 Dose 4 on Week 12; IFN-K
GSM5604136	Whole blood, SLE Patient 142 Dose 4 on Week 12 ; IFN-K
GSM5604137	Whole blood, SLE Patient 105 Dose 5 on Week 24 ; IFN-K
GSM5604138	Whole blood, SLE patient 23 Follow-up on Week 36, placebo
GSM5604139	Whole blood, SLE patient 59 Follow-up on Week 36, placebo
GSM5604140	Whole blood, SLE Patient 105 Follow-up on Week 36 ; IFN-K
GSM5604141	Whole blood, SLE Patient 155 Dose 1 on Week 0; IFN-K
GSM5604142	Whole blood, SLE Patient 155 Follow-up on Week 36 ; IFN-K
GSM5604143	Whole blood, SLE patient 59 Dose 1 on Week 0, placebo
GSM5604144	Whole blood, SLE patient 23 Dose 1 on Week 0, placebo
GSM5604145	Whole blood, SLE Patient 105 Dose 1 on Week 0; IFN-K
GSM5604146	Whole blood, SLE patient 59 Dose 5 on Week 24, placebo
GSM5604147	Whole blood, SLE Patient 155 Dose 5 on Week 24 ; IFN-K
GSM5604148	Whole blood, SLE patient 23 Dose 5 on Week 24, placebo
GSM5604149	Whole blood, SLE Patient 142 Dose 5 on Week 24 ; IFN-K
GSM5604150	Whole blood, SLE Patient 142 Follow-up on Week 36 ; IFN-K
GSM5604151	Whole blood, SLE patient 68 Follow-up on Week 36, placebo
GSM5604152	Whole blood, SLE patient 48 Dose 5 on Week 24, placebo
GSM5604153	Whole blood, SLE Patient 163 Dose 5 on Week 24; IFN-K
GSM5604154	Whole blood, SLE Patient 162 Dose 5 on Week 24; IFN-K
GSM5604155	Whole blood, SLE Patient 128 Dose 5 on Week 24; IFN-K
GSM5604156	Whole blood, SLE patient 68 Dose 5 on Week 24, placebo
GSM5604157	Whole blood, SLE Patient 160 Dose 5 on Week 24 ; IFN-K
GSM5604158	Whole blood, SLE Patient 128 Follow-up on Week 36; IFN-K
GSM5604159	Whole blood, SLE patient 48 Follow-up on Week 36, placebo
GSM5604160	Whole blood, SLE patient 43 Follow-up on Week 36, placebo
GSM5604161	Whole blood, SLE Patient 162 Follow-up on Week 36; IFN-K
GSM5604162	Whole blood, SLE Patient 163 Follow-up on Week 36; IFN-K
GSM5604163	Whole blood, SLE Patient 162 Dose 1 on Week 0; IFN-K
GSM5604164	Whole blood, SLE patient 48 Dose 1 on Week 0, placebo
GSM5604165	Whole blood, SLE Patient 128 Dose 1 on Week 0; IFN-K
GSM5604166	Whole blood, SLE Patient 163 Dose 1 on Week 0; IFN-K
GSM5604167	Whole blood, SLE patient 43 Dose 1 on Week 0, placebo
GSM5604168	Whole blood, SLE patient 68 Dose 1 on Week 0, placebo
GSM5604169	Whole blood, SLE Patient 160 Dose 1 on Week 0; IFN-K
GSM5604170	Whole blood, SLE Patient 128 Dose 4 on Week 12; IFN-K
GSM5604171	Whole blood, SLE Patient 162 Dose 4 on Week 12; IFN-K
GSM5604172	Whole blood, SLE Patient 163 Dose 4 on Week 12; IFN-K
GSM5604173	Whole blood, SLE patient 48 Dose 4 on Week 12, placebo
GSM5604174	Whole blood, SLE patient 68 Dose 4 on Week 12, placebo
GSM5604175	Whole blood, SLE patient 43 Dose 4 on Week 12, placebo
GSM5604176	Whole blood, SLE Patient 160 Follow-up on Week 36 ; IFN-K
GSM5604177	Whole blood, SLE Patient 160 Dose 4 on Week 12 ; IFN-K
GSM5604178	Whole blood, SLE patient 43 Dose 5 on Week 24, placebo
GSM5604179	Whole blood, SLE patient 82 Follow-up on Week 36, placebo
GSM5604180	Whole blood, SLE patient 81 Follow-up on Week 36, placebo
GSM5604181	Whole blood, SLE patient 79 Follow-up on Week 36, placebo
GSM5604182	Whole blood, SLE patient 74 Follow-up on Week 36, placebo
GSM5604183	Whole blood, SLE Patient 167 Follow-up on Week 36 ; IFN-K
GSM5604184	Whole blood, SLE patient 72 Dose 4 on Week 12, placebo
GSM5604185	Whole blood, SLE patient 22 Dose 5 on Week 24, placebo
GSM5604186	Whole blood, SLE Patient 154 Dose 4 on Week 12 ; IFN-K
GSM5604187	Whole blood, SLE patient 79 Dose 4 on Week 12, placebo
GSM5604188	Whole blood, SLE Patient 167 Dose 4 on Week 12 ; IFN-K
GSM5604189	Whole blood, SLE patient 82 Dose 4 on Week 12, placebo
GSM5604190	Whole blood, SLE patient 81 Dose 4 on Week 12, placebo
GSM5604191	Whole blood, SLE patient 80 Dose 4 on Week 12, placebo
GSM5604192	Whole blood, SLE Patient 168 Dose 4 on Week 12 ; IFN-K
GSM5604193	Whole blood, SLE patient 60 Dose 5 on Week 24, placebo
GSM5604194	Whole blood, SLE Patient 167 Dose 5 on Week 24 ; IFN-K
GSM5604195	Whole blood, SLE Patient 154 Follow-up on Week 36 ; IFN-K
GSM5604196	Whole blood, SLE patient 73 Dose 4 on Week 12, placebo
GSM5604197	Whole blood, SLE patient 60 Follow-up on Week 36, placebo
GSM5604198	Whole blood, SLE patient 73 Follow-up on Week 36, placebo
GSM5604199	Whole blood, SLE patient 72 Follow-up on Week 36, placebo
GSM5604200	Whole blood, SLE patient 80 Follow-up on Week 36, placebo
GSM5604201	Whole blood, SLE Patient 168 Follow-up on Week 36 ; IFN-K
GSM5604202	Whole blood, SLE patient 22 Dose 1 on Week 0, placebo
GSM5604203	Whole blood, SLE Patient 167 Dose 1 on Week 0; IFN-K
GSM5604204	Whole blood, SLE patient 60 Dose 1 on Week 0, placebo
GSM5604205	Whole blood, SLE Patient 168 Dose 1 on Week 0; IFN-K
GSM5604206	Whole blood, SLE patient 74 Dose 1 on Week 0, placebo
GSM5604207	Whole blood, SLE patient 60 Dose 4 on Week 12, placebo
GSM5604208	Whole blood, SLE patient 72 Dose 1 on Week 0, placebo
GSM5604209	Whole blood, SLE patient 81 Dose 1 on Week 0, placebo
GSM5604210	Whole blood, SLE patient 22 Dose 4 on Week 12, placebo
GSM5604211	Whole blood, SLE patient 80 Dose 1 on Week 0, placebo
GSM5604212	Whole blood, SLE Patient 154 Dose 1 on Week 0; IFN-K
GSM5604213	Whole blood, SLE patient 79 Dose 1 on Week 0, placebo
GSM5604214	Whole blood, SLE patient 82 Dose 1 on Week 0, placebo
GSM5604215	Whole blood, SLE patient 73 Dose 1 on Week 0, placebo
GSM5604216	Whole blood, SLE patient 74 Dose 4 on Week 12, placebo
GSM5604217	Whole blood, SLE patient 74 Dose 5 on Week 24, placebo
GSM5604218	Whole blood, SLE patient 73 Dose 5 on Week 24, placebo
GSM5604219	Whole blood, SLE patient 22 Follow-up on Week 36, placebo
GSM5604220	Whole blood, SLE patient 82 Dose 5 on Week 24, placebo
GSM5604221	Whole blood, SLE Patient 168 Dose 5 on Week 24 ; IFN-K
GSM5604222	Whole blood, SLE patient 79 Dose 5 on Week 24, placebo
GSM5604223	Whole blood, SLE Patient 154 Dose 5 on Week 24 ; IFN-K
GSM5604224	Whole blood, SLE patient 80 Dose 5 on Week 24, placebo
GSM5604225	Whole blood, SLE patient 81 Dose 5 on Week 24, placebo
GSM5604226	Whole blood, SLE patient 72 Dose 5 on Week 24, placebo
GSM5604227	Whole blood, SLE Patient 132 Dose 4 on Week 12; IFN-K
GSM5604228	Whole blood, SLE Patient 133 Dose 4 on Week 12; IFN-K
GSM5604229	Whole blood, SLE Patient 127 Dose 4 on Week 12; IFN-K
GSM5604230	Whole blood, SLE Patient 161 Dose 4 on Week 12; IFN-K
GSM5604231	Whole blood, SLE Patient 132 Dose 5 on Week 24 ; IFN-K
GSM5604232	Whole blood, SLE Patient 127 Dose 5 on Week 24 ; IFN-K
GSM5604233	Whole blood, SLE Patient 133 Dose 5 on Week 24 ; IFN-K
GSM5604234	Whole blood, SLE Patient 161 Dose 5 on Week 24 ; IFN-K
GSM5604235	Whole blood, SLE Patient 132 Dose 1 on Week 0; IFN-K
GSM5604236	Whole blood, SLE Patient 133 Dose 1 on Week 0; IFN-K
GSM5604237	Whole blood, SLE Patient 161 Dose 1 on Week 0; IFN-K
GSM5604238	Whole blood, SLE Patient 127 Dose 1 on Week 0; IFN-K
GSM5604239	Whole blood, SLE Patient 132 Follow-up on Week 36 ; IFN-K
GSM5604240	Whole blood, SLE Patient 133 Follow-up on Week 36 ; IFN-K
GSM5604241	Whole blood, SLE Patient 161 Follow-up on Week 36; IFN-K
GSM5604242	Whole blood, SLE Patient 127 Follow-up on Week 36 ; IFN-K
GSM5604243	Whole blood, SLE Patient 122 Follow-up on Week 36 ; IFN-K
GSM5604244	Whole blood, SLE patient 38 Follow-up on Week 36, placebo
GSM5604245	Whole blood, SLE patient 14 Follow-up on Week 36, placebo
GSM5604246	Whole blood, SLE patient 14 Dose 4 on Week 12, placebo
GSM5604247	Whole blood, SLE Patient 122 Dose 4 on Week 12; IFN-K
GSM5604248	Whole blood, SLE patient 38 Dose 4 on Week 12, placebo
GSM5604249	Whole blood, SLE Patient 121 Dose 5 on Week 24; IFN-K
GSM5604250	Whole blood, SLE patient 7 Dose 5 on Week 24, placebo
GSM5604251	Whole blood, SLE Patient 122 Dose 1 on Week 0; IFN-K
GSM5604252	Whole blood, SLE Patient 121 Dose 1 on Week 0; IFN-K
GSM5604253	Whole blood, SLE Patient 118 Dose 4 on Week 12; IFN-K
GSM5604254	Whole blood, SLE Patient 118 Dose 1 on Week 0; IFN-K
GSM5604255	Whole blood, SLE patient 36 Dose 1 on Week 0, placebo
GSM5604256	Whole blood, SLE patient 38 Dose 1 on Week 0, placebo
GSM5604257	Whole blood, SLE patient 7 Dose 1 on Week 0, placebo
GSM5604258	Whole blood, SLE patient 14 Dose 1 on Week 0, placebo
GSM5604259	Whole blood, SLE patient 36 Dose 4 on Week 12, placebo
GSM5604260	Whole blood, SLE Patient 121 Dose 4 on Week 12; IFN-K
GSM5604261	Whole blood, SLE patient 7 Dose 4 on Week 12, placebo
GSM5604262	Whole blood, SLE Patient 95 Dose 4 on Week 12; IFN-K
GSM5604263	Whole blood, SLE Patient 95 Dose 5 on Week 24; IFN-K
GSM5604264	Whole blood, SLE Patient 122 Dose 5 on Week 24 ; IFN-K
GSM5604265	Whole blood, SLE patient 38 Dose 5 on Week 24, placebo
GSM5604266	Whole blood, SLE Patient 118 Dose 5 on Week 24; IFN-K
GSM5604267	Whole blood, SLE patient 36 Dose 5 on Week 24, placebo
GSM5604268	Whole blood, SLE patient 14 Dose 5 on Week 24, placebo
GSM5604269	Whole blood, SLE Patient 95 Dose 1 on Week 0; IFN-K
GSM5604270	Whole blood, SLE patient 36 Follow-up on Week 36, placebo
GSM5604271	Whole blood, SLE Patient 118 Follow-up on Week 36 ; IFN-K
GSM5604272	Whole blood, SLE Patient 121 Follow-up on Week 36 ; IFN-K
GSM5604273	Whole blood, SLE patient 7 Follow-up on Week 36, placebo
GSM5604274	Whole blood, SLE Patient 95 Follow-up on Week 36 ; IFN-K
GSM5604275	Whole blood, SLE Patient 166 Dose 4 on Week 12; IFN-K
GSM5604276	Whole blood, SLE patient 70 Dose 5 on Week 24, placebo
GSM5604277	Whole blood, SLE Patient 166 Dose 5 on Week 24; IFN-K
GSM5604278	Whole blood, SLE patient 70 Follow-up on Week 36, placebo
GSM5604279	Whole blood, SLE Patient 166 Follow-up on Week 36; IFN-K
GSM5604280	Whole blood, SLE patient 70 Dose 1 on Week 0, placebo
GSM5604281	Whole blood, SLE Patient 166 Dose 1 on Week 0; IFN-K
GSM5604282	Whole blood, SLE patient 70 Dose 4 on Week 12, placebo
GSM5604283	Whole blood, SLE patient 75 Dose 1 on Week 0, placebo
GSM5604284	Whole blood, SLE patient 77 Dose 1 on Week 0, placebo
GSM5604285	Whole blood, SLE Patient 169 Follow-up on Week 36 ; IFN-K
GSM5604286	Whole blood, SLE Patient 157 Follow-up on Week 36 ; IFN-K
GSM5604287	Whole blood, SLE patient 66 Follow-up on Week 36, placebo
GSM5604288	Whole blood, SLE patient 76 Dose 1 on Week 0, placebo
GSM5604289	Whole blood, SLE patient 75 Follow-up on Week 36, placebo
GSM5604290	Whole blood, SLE Patient 171 Follow-up on Week 36 ; IFN-K
GSM5604291	Whole blood, SLE patient 76 Follow-up on Week 36, placebo
GSM5604292	Whole blood, SLE patient 77 Follow-up on Week 36, placebo
GSM5604293	Whole blood, SLE Patient 157 Dose 1 on Week 0; IFN-K
GSM5604294	Whole blood, SLE Patient 169 Dose 1 on Week 0; IFN-K
GSM5604295	Whole blood, SLE Patient 171 Dose 1 on Week 0; IFN-K
GSM5604296	Whole blood, SLE patient 66 Dose 5 on Week 24, placebo
GSM5604297	Whole blood, SLE patient 77 Dose 5 on Week 24, placebo
GSM5604298	Whole blood, SLE Patient 171 Dose 5 on Week 24 ; IFN-K
GSM5604299	Whole blood, SLE patient 66 Dose 4 on Week 12, placebo
GSM5604300	Whole blood, SLE patient 66 Dose 1 on Week 0, placebo
GSM5604301	Whole blood, SLE Patient 157 Dose 4 on Week 12; IFN-K
GSM5604302	Whole blood, SLE patient 75 Dose 4 on Week 12, placebo
GSM5604303	Whole blood, SLE patient 76 Dose 4 on Week 12, placebo
GSM5604304	Whole blood, SLE patient 77 Dose 4 on Week 12, placebo
GSM5604305	Whole blood, SLE Patient 171 Dose 4 on Week 12 ; IFN-K
GSM5604306	Whole blood, SLE Patient 169 Dose 4 on Week 12 ; IFN-K
GSM5604307	Whole blood, SLE patient 76 Dose 5 on Week 24, placebo
GSM5604308	Whole blood, SLE Patient 100 Dose 1 on Week 0; IFN-K
GSM5604309	Whole blood, SLE Patient 100 Follow-up on Week 36 ; IFN-K
GSM5604310	Whole blood, SLE Patient 100 Dose 4 on Week 12 ; IFN-K
GSM5604311	Whole blood, SLE Patient 100 Dose 5 on Week 24 ; IFN-K
GSM5604312	Whole blood, SLE patient 75 Dose 5 on Week 24, placebo
GSM5604313	Whole blood, SLE Patient 169 Dose 5 on Week 24 ; IFN-K
GSM5604314	Whole blood, SLE Patient 157 Dose 5 on Week 24 ; IFN-K
GSM5604315	Whole blood, SLE Patient 134 Follow-up on Week 36 ; IFN-K
GSM5604316	Whole blood, SLE Patient 164 Dose 5 on Week 24 ; IFN-K
GSM5604317	Whole blood, SLE patient 49 Dose 5 on Week 24, placebo
GSM5604318	Whole blood, SLE Patient 129 Dose 5 on Week 24 ; IFN-K
GSM5604319	Whole blood, SLE Patient 159 Dose 5 on Week 24 ; IFN-K
GSM5604320	Whole blood, SLE patient 49 Follow-up on Week 36, placebo
GSM5604321	Whole blood, SLE patient 44 Dose 4 on Week 12, placebo
GSM5604322	Whole blood, SLE Patient 129 Dose 4 on Week 12; IFN-K
GSM5604323	Whole blood, SLE Patient 164 Dose 1 on Week 0; IFN-K
GSM5604324	Whole blood, SLE Patient 134 Dose 4 on Week 12 ; IFN-K
GSM5604325	Whole blood, SLE Patient 129 Follow-up on Week 36 ; IFN-K
GSM5604326	Whole blood, SLE patient 49 Dose 1 on Week 0, placebo
GSM5604327	Whole blood, SLE patient 46 Dose 4 on Week 12, placebo
GSM5604328	Whole blood, SLE Patient 134 Dose 5 on Week 24 ; IFN-K
GSM5604329	Whole blood, SLE Patient 164 Dose 4 on Week 12 ; IFN-K
GSM5604330	Whole blood, SLE Patient 129 Dose 1 on Week 0; IFN-K
GSM5604331	Whole blood, SLE patient 49 Dose 4 on Week 12, placebo
GSM5604332	Whole blood, SLE Patient 159 Dose 4 on Week 12 ; IFN-K
GSM5604333	Whole blood, SLE Patient 134 Dose 1 on Week 0; IFN-K
GSM5604334	Whole blood, SLE patient 44 Dose 1 on Week 0, placebo
GSM5604335	Whole blood, SLE Patient 159 Dose 1 on Week 0; IFN-K
GSM5604336	Whole blood, SLE patient 44 Follow-up on Week 36, placebo
GSM5604337	Whole blood, SLE Patient 159 Follow-up on Week 36 ; IFN-K
GSM5604338	Whole blood, SLE Patient 113 Follow-up on Week 36; IFN-K
GSM5604339	Whole blood, SLE Patient 89 Dose 5 on Week 24; IFN-K
GSM5604340	Whole blood, SLE patient 25 Follow-up on Week 36, placebo
GSM5604341	Whole blood, SLE Patient 108 Follow-up on Week 36; IFN-K
GSM5604342	Whole blood, SLE patient 12 Dose 5 on Week 24, placebo
GSM5604343	Whole blood, SLE patient 12 Dose 1 on Week 0, placebo
GSM5604344	Whole blood, SLE patient 39 Follow-up on Week 36, placebo
GSM5604345	Whole blood, SLE Patient 89 Dose 4 on Week 12 ; IFN-K
GSM5604346	Whole blood, SLE Patient 113 Dose 4 on Week 12; IFN-K
GSM5604347	Whole blood, SLE patient 39 Dose 1 on Week 0, placebo
GSM5604348	Whole blood, SLE Patient 126 Follow-up on Week 36 ; IFN-K
GSM5604349	Whole blood, SLE Patient 89 Follow-up on Week 36; IFN-K
GSM5604350	Whole blood, SLE patient 25 Dose 1 on Week 0, placebo
GSM5604351	Whole blood, SLE Patient 108 Dose 1 on Week 0; IFN-K
GSM5604352	Whole blood, SLE Patient 89 Dose 1 on Week 0; IFN-K
GSM5604353	Whole blood, SLE patient 27 Dose 1 on Week 0, placebo
GSM5604354	Whole blood, SLE Patient 113 Dose 1 on Week 0; IFN-K
GSM5604355	Whole blood, SLE Patient 126 Dose 1 on Week 0; IFN-K
GSM5604356	Whole blood, SLE patient 25 Dose 5 on Week 24, placebo
GSM5604357	Whole blood, SLE Patient 108 Dose 5 on Week 24; IFN-K
GSM5604358	Whole blood, SLE Patient 113 Dose 5 on Week 24; IFN-K
GSM5604359	Whole blood, SLE patient 27 Dose 5 on Week 24, placebo
GSM5604360	Whole blood, SLE Patient 126 Dose 5 on Week 24 ; IFN-K
GSM5604361	Whole blood, SLE patient 39 Dose 5 on Week 24, placebo
GSM5604362	Whole blood, SLE Patient 108 Dose 4 on Week 12; IFN-K
GSM5604363	Whole blood, SLE patient 25 Dose 4 on Week 12, placebo
GSM5604364	Whole blood, SLE patient 39 Dose 4 on Week 12, placebo
GSM5604365	Whole blood, SLE Patient 126 Dose 4 on Week 12; IFN-K
GSM5604366	Whole blood, SLE patient 27 Follow-up on Week 36, placebo
GSM5604367	Whole blood, SLE patient 12 Follow-up on Week 36, placebo
GSM5604368	Whole blood, SLE patient 12 Dose 4 on Week 12, placebo
GSM5604369	Whole blood, SLE patient 27 Dose 4 on Week 12, placebo
GSM5604370	Whole blood, SLE Patient 164 Follow-up on Week 36 ; IFN-K
GSM5604371	Whole blood, SLE patient 8 Dose 4 on Week 12, placebo
GSM5604372	Whole blood, SLE Patient 109 Dose 4 on Week 12; IFN-K
GSM5604373	Whole blood, SLE patient 13 Dose 4 on Week 12, placebo
GSM5604374	Whole blood, SLE Patient 123 Dose 4 on Week 12 ; IFN-K
GSM5604375	Whole blood, SLE Patient 124 Dose 4 on Week 12 ; IFN-K
GSM5604376	Whole blood, SLE Patient 96 Dose 4 on Week 12 ; IFN-K
GSM5604377	Whole blood, SLE Patient 96 Dose 1 on Week 0; IFN-K
GSM5604378	Whole blood, SLE Patient 123 Dose 1 on Week 0; IFN-K
GSM5604379	Whole blood, SLE Patient 124 Dose 5 on Week 24 ; IFN-K
GSM5604380	Whole blood, SLE Patient 109 Dose 1 on Week 0; IFN-K
... Accession list truncated, click here to browse through all related public accessions You can also download a list of all accessions here